The repositionable aortic valve system allows to improve the functioning of the aortic valve in symptomatic patients with severe calcified aortic stenosis (aortic aortic area [AVA] of <1.0 cm2 or index of <0.6 cm2 / m2) and high risk for a substitution Conventional surgical valvular.
WATCHMAN FLX / WS5020, WS5024, WS5027, WS5031 and WS5035, specific batches.
Description du dispositif
The closure technology of the left atrial appendage WATCHMAN was designed to avoid embolization of the atrial appendage of the left atrial appendage and reduce the risk of life-threatening hemorrhage in nonvalvular atrial confibrillation patients who are suitable for anticoagulant treatment or who present a contraindication for anticoagulant treatment. of instructions for use: reinforcing the existing instructions for use to offer greater guidance regarding the correct use of the hemostasis valve to avoid coiling and to securely seal the valve. Minimizing the possibility of undesirable blood leakage, which could prevent potentially adverse events from occurring. the patient.
H749LTV230, H749LTV250, H749LTV270, H749LTVR3CL230, H749LTVR3CL250 and H749LTVR3CL270, specific batches.
Description du dispositif
The repositionable aortic valve system allows to improve the functioning of the aortic valve in symptomatic patients with severe calcified aortic stenosis (aortic aortic area [AVA] of <1.0 cm2 or index of <0.6 cm2 / m2) and high risk for a substitution Conventional surgical valvular.
The repositionable aortic valve system allows to improve the functioning of the aortic valve in symptomatic patients with severe calcified aortic conestenosis (aortic valve area [AVA] of <1.0 cm2 or index of <0.6 cm2 / m2) and high risk for a conventional surgical valvular replacement.
Indicated for patients with symptomatic congestive heart failure, including left ventricular dysfunction and a wide range of QRS, as well as one or more of the following conditions: - paroxysmal or permanent symptomatic second and third degree AV block. -blocking of bilateral symptomatic branch. - dysfunction of the paroxysmal or transient sinus-synomatic node with or without associated AV conduction disorder (eg sinus bradycardia, sinus arrest, neuroauricular block (SA) - bradycardia - tachycardia syndrome, to prevent symptomatic bradycardia or certain forms of symptomatic tachyarrhythmias.
Administer defibrillation treatment for the treatment of life-threatening ventricular tachyarrhythmias in patients who do not present with symptomatic bradycardia, incessant ventricular tachycardia, or frequent recurrent spontaneous ventricular tachycardia that are safely determined with cardiac pacing contrataquicardias.
Indicated to reinforce tissue and stabilize the fascia structure of the pelvic floor in case of prolapse of the vaginal wall, where a surgical treatment is required, either as a mechanical reinforcement or to join material in case of fascial dysfunction.
These defibrillators for cardiac resynchronization therapy (CRT-D) are indicated for patients who are at risk of suffering a cardiac death due to ventricular arrhythmias and heart failure, including ischemic heart failure (NYHA class I), with ventricular dyssynchrony. CRT-D are also indicated to provide ventricular tachycardia and ventricular defibrillation for the automated treatment of life-threatening ventricular arrhythmias.